APAC’s sweeping drug pricing reforms are rewriting the rules of market access in 2026. Pharma companies must strategically balance pricing caps with innovation to maintain a competitive edge. Filed under Asia-Pacific Australia China Global Japan South Korea Company & Commercial Healthcare & Life Sciences Topics Approved drug Generic drug Health insurance Inflation Over-the-counter drug Pharmaceuticals Supply chain Organisations GlobalData Organisation for Economic Co-operation and Development The Sri Lanka Gazette Industries Agribusiness & food Biotechnology & medical research Food & drug retailers Healthcare Pharmaceuticals Pharmaceuticals & chemicals
